Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...

The U.S. kicked off an an unprecedented inoculation campaign this week with a COVID-19 vaccine from Pfizer and its German partner BioNTech. Another vaccine from Moderna, which was co-developed with ...

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

Moderna has early in-human data showing its next-generation COVID-19 vaccine, mNEXSPIKE, has the potential to offer strong immune protection against the latest rapidly spreading SARS-CoV-2 virus.

Moderna Inc became the second U.S company to release data from a large study of its experimental vaccine, saying it was 94.5% effective against COVID-19.

The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand ...

Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand ...